This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting (POM MM 014)

This study is currently recruiting participants.
See Contacts and Locations
Verified June 2017 by Celgene
Sponsor:
Information provided by (Responsible Party):
Celgene
ClinicalTrials.gov Identifier:
NCT01946477
First received: September 17, 2013
Last updated: June 16, 2017
Last verified: June 2017
  Purpose

This trial will evaluate the efficacy and safety of combination of pomalidomide (POM) and low-dose dexamethasone (LD-Dex) (Cohort A) or the combination of pomalidomide (POM) , daratumumab (DARA) and low-dose dexamethasone (LD-Dex) (Cohort B) in subjects with relapsed or refractory multiple myeloma who have received a first or second line treatment of lenalidomide-based therapy.

This trial will test the hypothesis for Cohort A that the proportion of patients will have an Overall Response Rate (ORR) of > 30 % to reveal that Pomalidomide is efficacious in pretreated patients who are refractory to lenalidomide.

This trial will test the hypothesis for Cohort B that the proportion of patients will have an Overall Response Rate (ORR) of > 70 % to reveal that POM+DARA+LD-Dex is efficacious in pretreated patients who are refractory to lenalidomide.


Condition Intervention Phase
Multiple Myeloma Drug: Pomalidomide Drug: Dexamethasone Drug: Daratumumab Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Phase 2, Multicenter, Multi-cohort, Open-label Study of Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide Based Therapy in the First or Second Line Setting.

Resource links provided by NLM:


Further study details as provided by Celgene:

Primary Outcome Measures:
  • Overall response rate (ORR) [ Time Frame: Approximately 2 years ]
    The primary endpoint will be the Overall Response Rate (ORR) by modified International Myeloma Working Group (mIMWG) criteria and will be based on the best response prior to the time frame. ORR will consist of the responses of PR or better (Complete Response -CR, Very Good Partial Response-VGPR or Partial Response- PR).


Secondary Outcome Measures:
  • Overall survival (OS) [ Time Frame: Up to 7 years ]
    Overall survival will be calculated as the time from start of treatment until the time of death from any cause. If no death is recorded the subject will be censored at the time the subject was last known to be alive.

  • Progression-free survival (PFS) [ Time Frame: Up to 7 years ]
    Progression-free survival will be calculated as the time from start of treatment until the time of PD (as determined by the site Investigator based on the mIMWG criteria) or death from any cause on study treatment, whichever comes first. Subjects not experiencing a documented progression will be censored at the time of their last response assessment (or at the time of trial enrollment if no assessment was conducted).

  • Duration of Response (DoR) [ Time Frame: Up to 7 years ]
    Duration of response, calculated for responders only, is defined as time from the initial documented response (PR or better) to the first confirmed PD or until death from any cause. Subjects without a documented progression will be censored at the time of their last response assessment

  • Time to Response (TTR) [ Time Frame: Up to 2 years ]
    Time to response, calculated for responders only, is calculated as the time from the start of treatment to the first documented response (PR or better) based on modified International Working Group ( mIMWG) criteria.

  • Time to progression (TTP) [ Time Frame: 6 months after 100% enrollment and 5 years from Last Patient First Visit ]
    Time to progression will be calculated as the time from start of treatment until PD (as determined by the site Investigator based on the mIMWG criteria) or death from progressive disease. Subjects not experiencing a documented progression will be censored at the time of their last response assessment (or at the time of trial enrollment if no assessment was conducted).

  • Adverse Events [ Time Frame: Up to 7 years ]
    Number of participants with adverse events including secondary primary malignancies.


Estimated Enrollment: 155
Actual Study Start Date: May 29, 2014
Estimated Study Completion Date: February 28, 2023
Estimated Primary Completion Date: December 31, 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Pomalidomide + dexamethasone
Each subject enrolled in the study will take oral pomalidomide (4 mg) once daily on Days 1-21 and dexamethasone 40 mg/day (< 75 years old) or 20 mg/day (>75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle.
Drug: Pomalidomide
Other Name: CC-4047
Drug: Dexamethasone
Other Name: dex
Experimental: Pomalidomide + Dexamethasone + Daratumumab

Each subject enrolled in the study will take oral pomalidomide (4 mg) once daily on Days 1-21 and dexamethasone 40 mg/day (< 75 years old) or 20 mg/ day (>75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle and daratumumab administered intravenously (IV) at a starting dose of 16 mg/kg at following schedule:

  • Days 1, 8, 15, and 22 of a 28-day cycle for Cycle 1 and Cycle 2
  • Days 1 and 15 for Cycle 3 through Cycle 6
  • Day 1 for Cycle 7 and each cycle thereafter until disease progression
Drug: Pomalidomide
Other Name: CC-4047
Drug: Dexamethasone
Other Name: dex
Drug: Daratumumab

Detailed Description:

A phase 2, multicenter, multi-cohort, open-label study of pomalidomide in combination with low-dose dexamethasone or pomalidomide in combination with low-dose dexamethasone and daratumumab in subjects with relapsed or refractory multiple myeloma following lenalidomide based therapy in the first or second line setting.

This trial will assess, Overall Response Rate (ORR), Overall Survival (OS), Progression-Free Survival (PFS), Duration of Response (DoR), Time to Response (TTR), Time to Progression(TTP) and safety.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

- Subjects must satisfy the following criteria to be enrolled in the study:

  1. Adults (age ≥ 18 years at the time of signing the ICD) with documented diagnosis of MM and measurable disease (serum M-protein ≥ 0.5 g/dL or urine M-protein ≥ 200 mg/24 hours).
  2. Subjects enrolling in Cohort A (Pom+LD-dex) must have received 2 prior treatment lines of anti-myeloma therapy. Subjects enrolling in Cohort B (Pom+Dara+LD-dex) must have received 1 or 2 prior treatment lines of anti-myeloma therapy.
  3. All subjects must have received prior treatment with LEN or a LEN-containing regimen for at least 2 consecutive cycles as the most recent treatment regimen.
  4. All subjects must have documented disease progression during or after their last antimyeloma therapy.
  5. Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.
  6. Subjects must understand and voluntarily sign an ICD prior to any study related assessments/procedures being conducted.
  7. Subjects must be able to adhere to the study visit schedule and other protocol requirements.
  8. All subjects must provide an adequate bone marrow sample at screening that definitively evaluates the presence or absence of myelodysplastic changes.
  9. Females with child-bearing potential (FCBP†) must agree to use 2 reliable forms of contraception* simultaneously or practice complete abstinence from heterosexual contact for at least 28 days before starting study drug, while participating in the study (including during dose interruptions), and for at least 28 days after study treatment discontinuation and must agree to regular pregnancy testing during this timeframe. For subjects enrolled in Cohort B, pregnancy prevention and testing will continue until 3 months after last dose of daratumumab.
  10. Females must agree to abstain from breastfeeding during study participation and 28 days after study drug discontinuation. Female subjects enrolled in Cohort B must agree to abstain from breastfeeding and donating eggs during study participation and until 3 months after last dose of daratumumab.
  11. Males must agree to use a latex condom during any sexual contact with FCBP while participating in the study and for 28 days following discontinuation from this study, even if he has undergone a successful vasectomy. Male subjects enrolled in Cohort B must agree to use a latex condom during any sexual contact with FCBP while participating in the study and until 3 months after last dose of daratumumab.
  12. Males must also agree to refrain from donating semen or sperm during the treatment phase and for 28 days after discontinuation from this study treatment. Male subjects enrolled in Cohort B must also agree to refrain from donating semen or sperm during the treatment phase and until 3 months after last dose of daratumumab.
  13. All subjects must agree to refrain from donating blood while on study therapy and for 28 days after discontinuation from this study treatment.
  14. All subjects must agree not to share medication.

Exclusion Criteria:

The presence of any of the following will exclude a subject from study enrollment:

  1. Any of the following laboratory abnormalities:

    • Absolute neutrophil count < 1,000/μL
    • Platelet count < 75,000/μL for subjects in whom < 50% of bone marrow nucleated cells are plasma cells; or a platelet count < 30,000/μL for subjects in whom ≥ 50% of bone marrow nucleated cells are plasma cells.
    • Severe renal impairment (Creatinine Clearance [CrCl] < 30 mL/min) requiring dialysis.
    • Corrected serum calcium > 11.5 mg/dL (> 2.8 mmol/L)
    • Hemoglobin < 8 g/dL (< 4.9 mmol/L; prior red blood cell transfusion or recombinant human erythropoietin use is permitted)
    • Serum SGOT/AST or SGPT/ALT > 3.0 x the upper limit of normal (ULN)
    • Serum total bilirubin > 2.0 mg/dL (34.2 μmol/L); or > 3.0 x ULN for subjects with hereditary benign hyperbilirubinemia
  2. Prior history of malignancies, other than MM, unless the subject has been free of the disease for ≥ 5 years. Allowed exceptions include the following:

    • Basal or squamous cell carcinoma of the skin
    • Carcinoma in situ of the cervix or breast
    • Incidental histological finding of prostate cancer (TNM [tumor, nodes, metastasis] stage of T1a or T1b)
  3. Previous therapy with pomalidomide or daratumumab
  4. Hypersensitivity to thalidomide, LEN, or dex (this includes ≥ Grade 3 rash during prior thalidomide or LEN therapy)
  5. Subjects who received an allogeneic bone marrow or allogeneic peripheral blood stem cell transplant less than 12 months prior to initiation of study treatment and who have not discontinued immunosuppressive treatment for at least 4 weeks prior to initiation of study treatment and are currently dependent on such treatment.
  6. Subjects with any one of the following:

    • Congestive heart failure (NY Heart Association Class III or IV)
    • Myocardial infarction within 12 months prior to starting study treatment
    • Unstable or poorly controlled angina pectoris, including Prinzmetal's variant angina pectoris
  7. Subjects who received any of the following within 14 days of initiation of study treatment:

    • Major surgery (kyphoplasty is not considered major surgery)
    • Use of any anti-myeloma drug therapy
  8. Use of any investigational agents within 28 days or 5 half-lives (whichever is longer) of treatment, unless approved by the sponsor.
  9. Incidence of gastrointestinal disease that may significantly alter the absorption of Pomalidomide.
  10. Subjects unable or unwilling to undergo antithrombotic prophylactic treatment
  11. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the ICD
  12. Pregnant or breastfeeding females
  13. Known human immunodeficiency virus (HIV) positivity; active infectious hepatitis A, B, or C; or chronic hepatitis B or C
  14. For subjects enrolling in Cohort B - Subject has known allergies, hypersensitivity to mannitol, corticosteroids, monoclonal antibodies or human proteins, or their excipients (refer to the Daratumumab IB), or known sensitivity to mammalian-derived products.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01946477

Contacts
Contact: Associate Director Clinical Trial Disclosure 1-888-260-1599 clinicaltrialdisclosure@celgene.com

  Show 42 Study Locations
Sponsors and Collaborators
Celgene
Investigators
Study Director: Jorge Mouro, MS Celgene Corporation
  More Information

Responsible Party: Celgene
ClinicalTrials.gov Identifier: NCT01946477     History of Changes
Other Study ID Numbers: CC-4047-MM-014
Study First Received: September 17, 2013
Last Updated: June 16, 2017

Keywords provided by Celgene:
Multiple Myeloma, MM, cancer, oncology, hematology, plasma, neoplasm, plasmacytoma

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Dexamethasone acetate
Dexamethasone
Dexamethasone 21-phosphate
Lenalidomide
Pomalidomide
Daratumumab
Thalidomide
BB 1101
Antibodies, Monoclonal
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids

ClinicalTrials.gov processed this record on June 22, 2017